Recurrent spontaneous abortion
Conditions
Interventions
Case group:No
control:No
Sponsors
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Aged 25-35 years old, no history of live births, consulted in the family planning department of our hospital, no induced spontaneous abortion 2 or more times, all occurred within 5-8 weeks of pregnancy; 2. regular menstruation, no other systemic Disease, no history of exposure to harmful substances; 3. Endocrine examination: determination of fasting blood follicle stimulating hormone (FSH) luteinizing hormone (LH), testosterone (T), prolactin (PRL), estradiol (E2), within 2-5 days after the second menstruation Thyroid stimulating hormone (TSH), all indexes are checked within the normal reference range for 2 consecutive times; 4. Determination of anti-cardiolipin antibody (ACA), anti-nuclear antibody (ANA), anti-double-stranded DNA antibody (dsDNA), anti-sperm antibody (AsAb) in the blood, IgM and IgG antibodies were negative; 5. Four eugenics were tested: rubella virus antibody, cytomegalovirus antibody, sores virus antibody, and toxoplasma antibody were negative; 6. Ultrasound examination of the anatomy of the reproductive system showed no abnormalities; 7. Chromosome karyotype analysis of both couples is normal.
Exclusion criteria
Exclusion criteria: 1. Patients with organic lesions of reproductive organs after examination (such as vaginal, cervical or uterine malformations, endometrial polyps, endometrial hyperplasia, intrauterine adhesions, uterine fibroids, uterine adenomyosis and ovarian tumors, hydrosalpinx Etc.); 2. patients with various liver, kidney or cardiovascular and blood system diseases, mental or mental diseases; 3. patients with other endocrine diseases, such as abnormal thyroid function, hyperprolactinemia, polycystic ovary syndrome and diabetes; 4. Patients who use other hormones, Chinese medicine and other adjuvant therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood estrogen receptor;Blood progesterone receptor;Endometrial calcitonin mRNA;Endometrial leukemia inhibitory factor-1 receptor;Endometrial growth hormone receptor; | — |
Countries
China
Contacts
Public ContactHu Qiaofei
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Outcome results
None listed